YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics' Syracuse facility in New York Strategic long-term partnership with Alvotech to increase their global manufacturing capacity and support growth in dema…
Alvotech (NasdaqGM:ALVO) is back in focus after two closely timed manufacturing updates that reshape how its biosimilars could be supplied to major markets. Both moves revolve around capacity, regulatory readiness, and long term supply sec…
* Alvotech (ALVO [https://seekingalpha.com/symbol/ALVO]) announced on Tuesday that it agreed to a long-term deal with LOTTE Biologics to manufacture multiple biosimilar drugs at its Syracuse, New York facility. * The deal adds 40K liters o…
Alvotech Alvotech and LOTTE Biologics signing ceremonyAlvotech and LOTTE Biologics signing ceremony to commemorate the formation of a strategic manufacturing agreement on October 6, 2026 Collaboration covers multiple biosimilar products to…
Investing.com -- Alvotech SA (NASDAQ:ALVO) shares jumped 13.5% Monday after the U.S. Food and Drug Administration approved a supplement to the Biologics License Application for AVT02, enabling the company to manufacture the drug substance…
Alvotech Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech's two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related matters at the Reykjavik site RE…
The biotech company’s stock rises after Barclays gives it a double upgrade, citing confidence in upcoming FDA approvals. Continue Reading
Alvotech REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S.…
Alvotech REYKJAVIK, Iceland, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announce…
Alvotech stock has fallen about 50% over the past three years, yet the valuation checks currently lean cheap and the market is reacting positively to fresh licensing deals and regulatory progress. Over the past three years the share price…
In August 2026, Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for biosimilar candidates AVT34 (Imfinzi) and AVT87 (Hemlibra) across the United States and eight Asian markets, with potential consid…
Alvotech has spent years building a biosimilar platform that Wall Street has struggled to value through regulatory delays, manufacturing investment, and uneven commercial results. Bank of America now thinks the investment case is entering…
Alvotech REYKJAVIK, ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Robert W…
Alvotech REYKJAVIK, Iceland, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announce…
Alvotech (NASDAQ:ALVO) extended its winning streak to a 5th consecutive day on Monday, jumping 18.51 percent to finish at $5.25 apiece, after the Bank of America (BofA) raised its price target for the company. In its recent coverage, BofA…
[Modern Medicine Research Laboratory: Diverse Team of Multi-Ethnic Young Scientists Passes Samples in Petri Dish. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs] gorodenkoff/iStock via Getty Images Al…
Investing.com -- BofA Securities initiated coverage of Alvotech S.A. with a "buy" rating and a $7 price objective, versus the stock's $4.43 price as of Monday, after the FDA's closure of its inspection of the company's Reykjavik manufactur…
Alvotech REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announce…
Alvotech REYKJAVIK, ICELAND (August 21, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic l…
Key Points Interested in Alvotech? Here are five stocks we like better. First-half results declined as manufacturing slowed during facility and quality-system improvements, with revenue falling to $212 million and adjusted EBITDA to $47 mi…
Alvotech (ALVO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.14 per share a year ago. These figures are adjusted for non-recurring items. This qua…
Alvotech REYKJAVIK, ICELAND (August 19, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,…
Amneal Pharmaceuticals AMRX completed its acquisition of Kashiv BioSciences on Monday, creating an integrated global biosimilars platform spanning research, development, manufacturing and commercialization. The deal broadens Amneal's biosi…
[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [ht…
X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $3.47 per share a year ago. These figures are adjusted for non-recurring items.…
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.12 per share a year ago. These figures are adjusted for non-recurring…
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $0.68 per share a year ago. These figures are adjusted for…
(RTTNews) - Today's top biotech gainers include SciSparc, after its subsidiary successfully completed internal validation of a proprietary quantum sampling platform designed to analyze clinical trial data; Avantor, following the release of…
(RTTNews) - Alvotech (ALVO), a biotechnology company focused on developing and manufacturing biosimilar medicines, announced that the U.S. FDA has successfully closed its inspection of the company's manufacturing facility in Reykjavik, Ice…
Alvotech REYKJAVIK, ICELAND (July 29, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced…
Alvotech REYKJAVIK, Iceland, July 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Alvotech stock is coming off a difficult stretch, with the share price down about 64% over the past five years, yet the…
Alvotech recently amended its credit agreement to add a new US$75 million term loan facility led by GoldenTree Asset Management, following a US$165 million equity raise in June 2026, giving the company access to US$240 million in additiona…
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2%, and the actively t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Alvotech (ALVO [https://seekingalpha.com/symbol/ALVO]) announced an amendment to its existing credit agreement [https://seekingalpha.com/pr/20569593-alvotech-further-strengthens-liquidity-by-securing-term-loan-facility-of-75-million], secu…
Alvotech — $75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset Management — Follows recent $165m equity raise strengthening cash position — Including equity financing and undrawn loan facility, Alv…